MONTREAL, Oct. 1 /CNW Telbec/ - The CQDM (Quebec Consortium for Drug
Discovery) launches its first call for proposals of its funding program
designed to support the development of innovative enabling tools that can
accelerate the drug discovery process.
"We are aimed at bringing together the many resources and talents of
Quebec to face the challenge of the drug discovery process. Our program
strongly encourages collaborative efforts between researchers from the
industrial and the academic sectors" said Mr. Max Fehlmann, President and CEO
of the CQDM.
The priority topic for 2008-2009 competition is Efficacy. Therefore, the
priority will be given to enabling technologies that are designed to:
1) accelerate the discovery of new drugs,
2) increase drug efficacy,
3) improve predictability of efficacy,
4) facilitate evaluation of efficacy.
CQDM's funding will be awarded following a competitive process in
2 stages. Applicants must submit a letter of intent before November 27th,
2008. The selection will be overseen by the CQDM's Strategic Orientation
Committee. Only applicants whose letter of intent will be selected will be
invited to submit a full project proposal before February 27th, 2009.
Evaluation of the proposals will involve an international peer review led by
the Fonds de la recherche en santé du Québec (FRSQ). Announcement of the final
selection will be made in April 2009.
"Thanks to our financial partners, the CQDM has the capacity this year to
fund 3 to 5 innovative projects for up to $3 M per project ($1 M/year for
3 years). We are proud of our funding program, as it represents an innovative
solution to the drug discovery industrial challenges" concluded Mr. Fehlmann.
The CQDM is a non-for-profit organization that responds to the needs of
the pharmaceutical industry by contributing to accelerating drug discovery and
developing safer and more effective drugs. The CQDM is a meeting ground for
reflection and analysis by all stakeholders in the drug industry. Its mission
is to identify, finance and support research projects carried out in
partnership between the academic and hospital milieus in the public and the
private sectors. Initial financing for the CQDM's operation is mainly provided
by a grant awarded by the Fonds de la recherche en santé du Québec (FRSQ), the
Ministry of Economic Development, Innovation and Export Trade (MDEIE) as well
as investments from Pfizer Canada, AstraZeneca Canada and Merck Frosst.
For further information:
For further information: Diane Gosselin, Vice president, Research and
Business Development, CQDM, (514) 766-6661, ext. 2191, email@example.com;